Peptide Science2 June 2026
Peptides, proteins, hormones, and small molecules are often conflated in popular discussion. This guide explains the structural, functional, and regulatory distinctions that matter for researchers and clinicians.
Regulatory Policy29 May 2026
Clinical trials involving peptide-based therapeutics are accelerating across oncology, metabolic disease, and tissue repair, but regulatory frameworks and public communication have not kept pace. The result is a widening information vacuum that grey markets are filling faster than governments.
Growth Hormone Secretagogues26 May 2026
Peptide stacking, the practice of combining multiple peptides concurrently, is widely discussed but poorly studied. This post examines what published research actually supports and where significant evidence gaps remain.
Research Methodology22 May 2026
A practical guide to critically evaluating peptide studies, covering study design hierarchies, the challenges of translating animal doses to human equivalents, and how to interpret effect sizes in published peptide research.
Regulation15 May 2026
Peptides occupy different regulatory classifications across major jurisdictions. This post examines how the FDA, EMA, MHRA, and TGA classify therapeutic peptides and what that means for research and clinical access.
Collagen Peptides12 May 2026
Collagen peptides and bioactive signalling peptides are frequently conflated in public discussion, but they differ in structure, mechanism, regulatory status, and quality of supporting evidence. This post examines what the research actually distinguishes between these two categories.
Safety8 May 2026
A research-focused overview of what published studies reveal about peptide side effects, contraindications, and the significant gaps in long-term safety data that researchers and clinicians should understand.
Bioavailability6 May 2026
Bioavailability determines how much of an administered peptide reaches systemic circulation. This post reviews what published research shows about subcutaneous, oral, and nasal delivery routes and the pharmacokinetic trade-offs each presents.
CJC-129528 April 2026
An evidence-based overview of CJC-1295 and ipamorelin, two growth hormone secretagogue peptides. This post examines their mechanisms of action, published clinical data, evidence limitations, and current regulatory status.
GHK-Cu21 April 2026
GHK-Cu is a naturally occurring copper-binding tripeptide studied for its effects on wound healing, skin remodeling, hair growth, and gene expression associated with aging. This profile reviews the published evidence, its limitations, and current regulatory context.
Thymosin Beta-420 April 2026
An evidence-based review of Thymosin Beta-4's role in wound healing, covering its molecular mechanism of action, preclinical findings in animal models, and the current state of human clinical evidence.
BPC-15717 April 2026
A research-level review of BPC-157 studies on gut healing and tissue repair, covering animal model evidence, mechanism of action hypotheses, and the significant gaps in human clinical data.
Peptide Science14 April 2026
An educational overview of how peptides are defined in biochemistry, what distinguishes them from proteins, hormones, and small molecules, and why these distinctions matter for research and regulatory classification.
Pathway Guides10 April 2026
Most peptides in Australia are classified as Schedule 4 (Prescription Only) under the Poisons Standard. Here's what that means for access and legality.
TGA Updates8 April 2026
A comprehensive look at the key peptide scheduling changes the TGA has implemented since mid-2025, including Melanotan II reclassification and compounding framework updates.
Pathway Guides5 April 2026
A step-by-step guide to legally accessing peptide therapies in Australia through prescription pathways, including costs and what to expect.
Market Intelligence28 March 2026
A detailed comparison of grey market peptide sources versus legitimate prescription access, covering quality, legality, cost, and health risks.
Global Regulatory20 March 2026
How the US FDA's Category 1 bulk drug substance list is affecting peptide availability and compounding supply chains in Australia.
Data Reports15 March 2026
Key data points from the Australian peptide market in Q1 2026, covering provider growth, prescribing trends, grey market activity, and enforcement actions.